Long-acting risperidone: a review of its role in the treatment of bipolar disorder

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Advances in Therapy

• Publication date

  2009-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-009-0039-0PMID 19562274PMCID PMC2878768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olanzapine pamoate: a stick in time?

  2009cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

  2009cited by this paper
• Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

  2009cited by this paper
• Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.

  2009cited by this paper
• Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients

  2008cited by this paper
• Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder.

  2008cited by this paper
• Bipolar drug development: are we getting closer to the real world?

  2008cited by this paper
• Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

  2008cited by this paper
• Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

  2008cited by this paper
• Frequently relapsing bipolar disorder: Evidence for an effective treatment

  2008cited by this paper
• The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD.

  2008cited by this paper
• A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

  2008cited by this paper
• Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression.

  2007cited by this paper
• Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

  2007cited by this paper
• Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.

  2007cited by this paper
• A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder

  2007cited by this paper
• Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.

  2007cited by this paper
• Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

  2007cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

  2006cited by this paper
• Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

  2006cited by this paper
• Treatment adherence with antipsychotic medications in bipolar disorder.

  2006cited by this paper
• Risperidone long‐acting injection in practice – more questions than answers?

  2006cited by this paper
• Use of long-acting risperidone in the treatment of bipolar patients.

  2006cited by this paper
• Mortality and medical comorbidity among patients with serious mental illness.

  2006cited by this paper
• Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

  2006cited by this paper
• A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

  2006cited by this paper
• Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

  2006cited by this paper
• Prevalence and treatment of mental disorders.

  2005cited by this paper
• Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.

  2005cited by this paper
• Prevalence and treatment of mental disorders, 1990 to 2003.

  2005cited by this paper
• Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.

  2005cited by this paper
• Atypical antipsychotics for bipolar disorder.

  2005cited by this paper
• The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

  2005cited by this paper
• Long-Acting Risperidone

  2004cited by this paper
• Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.

  2004cited by this paper
• Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• Rapid‐cycling bipolar disorder: effects of long‐term treatments

  2003cited by this paper
• Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.

  2003cited by this paper
• Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

  2003cited by this paper
• Mood stabilisers plus risperidone or placebo in the treatment of acute mania

  2003cited by this paper
• Mortality of patients with mood disorders: follow-up over 34-38 years.

  2002cited by this paper
• Atypical Antipsychotics: Mechanism of Action

  2002cited by this paper
• Nonadherence with mood stabilizers: prevalence and predictors.

  2002cited by this paper
• Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.

  2002cited by this paper
• Excess mortality in bipolar and unipolar disorder in Sweden.

  2001cited by this paper
• The global burden of disease in 1990: summary results, sensitivity analysis and future directions.

  1994cited by this paper
• Manic-Depressive Illness

  1990cited by this paper

• Enhancing oral bioavailability of escitalopram by self-nanoemulsifying drug delivery systems (SNEDDS): An in-vivo, in-vitro and in-silico study.

  2025cites this paper
• The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment

  2025cites this paper
• Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

  2025cites this paper
• Low Oxygen Saturation During Risperidone Therapy: A Multispecialty Approach

  2025cites this paper
• The role of neuroinflammation in schizophrenia: Focus on Th17 cells functions.

  2025cites this paper
• Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications

  2024cites this paper
• Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L.

  2023cites this paper
• Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder.

  2022cites this paper
• Histological Changes of Maternal Risperidone and Folic acid on the Cerebellar Cortex of the Offspring of the Albino Rat

  2019cites this paper
• The effects of Risperidone on the vestibular system of healthy volunteers as assessed by dynamic computed posturography

  2017cites this paper
• Smartphone Applications for Educating and Helping Non-motivating Patients Adhere to Medication That Treats Mental Health Conditions: Aims and Functioning

  2017cites this paper
• Piperidine-Based Nonfused Biheterocycles With C–N and C–C Coupling

  2017cites this paper
• Formulation and Characterization of Carrier Vehicles for Infectious Disease Treatment and Modulation of the Innate Immune System

  2017cites this paper
• Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable

  2016cites this paper
• Long-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child.

  2016cites this paper
• A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder

  2015cites this paper
• Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder.

  2013cites this paper
• Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

  2011cites this paper
• Tratamento de prevenção secundária

  2011cites this paper
• Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder

  2010cites this paper
• Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

  2010cites this paper
• Bipolar Depression: Overview and Commentary

  2010cites this paper
• Risperidone Long-Acting Injection

  2010cites this paper